VAERS reports by lot

GSK DTaP/Tdap lot LS444: VAERS reports

30 VAERS reports list lot LS444 as a GSK DTaP/Tdap vaccine, received between 2022-04-05 and 2023-10-20. Data: VAERS public files through 28 May 2026 (site extract 2026-10-28).

Read this first. VAERS accepts reports from anyone, and a report does not establish that the vaccine caused the event. A lot's report count mostly reflects how many doses it contained, when it was used and who received it; no administered-dose counts are published for this lot, so counts are not rates and cannot rank lots against each other. Lot numbers in VAERS reports are typed by reporters and are sometimes wrong.
30
Reports
0%
Marked serious
0
With a death outcome
14
Months with reports

Symptom categories in these reports

A report can mention several categories, so the counts add up to more than the number of reports.

CategoryCount%
Injection-site / Local reaction1267%
Allergic / Anaphylactic317%
Dermatological (non-injection-site)211%
Neurological16%

Where reports came from

U.S. state of the reporter, where given (top 12).

StateReports
Alabama4
Oklahoma3
Texas2
West Virginia2
Ohio2
Iowa2
Michigan2
Tennessee2
Illinois2
California1
Idaho1
Connecticut1

Reports by month received

MonthReportsBar
2022-041
2022-051
2022-075
2022-082
2022-094
2022-101
2022-111
2022-121
2023-012
2023-031
2023-041
2023-051
2023-094
2023-105

Products recorded with this lot

Manufacturer and product as reported in VAERS. Reports listing the lot under more than one product are counted once.

Related

Nearby GSK DTaP/Tdap lots (A–Z): K5F5R · L5229 · LP2G2 · MF9EA · PG3RP · PP9L5

Source: VAERS public data (CDC/FDA), grouped by manufacturer and lot by the Open Source Medicine Foundation; extract 2026-10-28 18:08 UTC. Not medical advice. Report errors via contact.